The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.

@article{Gallant2008The3R,
  title={The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.},
  author={Joel E. Gallant and Jonathan A. Winston and Edwin Dejesus and Anton Louis Pozniak and Shan-Shan Chen and A. S. K. Cheng and Jeffrey V Enejosa},
  journal={AIDS},
  year={2008},
  volume={22 16},
  pages={2155-63}
}
BACKGROUND Cases of renal dysfunction in patients receiving tenofovir disoproxil fumarate (TDF) have been reported. We analyzed the renal safety of TDF compared with thymidine analogue-containing (control) regimens through 144 weeks from two clinical trials in antiretroviral-naive HIV-infected patients. METHODS We evaluated the changes in renal parameters… CONTINUE READING